Shares of Terns Pharmaceuticals (TERN) surged after the company updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia. The shares are up roughly 40% to over $41 in afternoon trading.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns CEO says ‘delighted’ by ‘unprecedented’ Phase 1 data for TERN-701
- Terns Parmaceuticles trading halted, news pending
- Terns Pharmaceuticals price target raised to $35 from $25 at Citizens JMP
- Terns Pharmaceuticals price target raised to $36 from $28 at Barclays
- Promising Outlook for TERN-701 in CML Market: Buy Rating Affirmed by Analyst